Clinical trial
A Phase II Clinical Trial of Suppression of Human Antimouse Antibody and Human Antitoxin Response to Immunotoxin LMB-1 by Rituximab
NCT00001805 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II Clinical Trial of Suppression of Human Antimouse Antibody and Human Antitoxin Response to Immunotoxin LMB-1 by Rituximab
- Lead sponsor
- National Cancer Institute (NCI)
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- March 31, 1999
- Completion date
- June 30, 2000
- Enrollment
- 20
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.